Cellectis S.A. American Depositary Shares

Cellectis announced final Phase 1 data for lasme-cel, an allogeneic CAR-T therapy targeting CD22 in relapsed/refractory B-cell acute lymphoblastic leukemia, showing 100% overall response rate in the target population with manageable safety profile. The company also presented preliminary data for eti-cel, a dual-targeted CAR-T therapy against CD20...

Cellectis announced final Phase 1 results from the BALLI-01 trial of lasme-cel, a CD22-directed allogeneic CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia, showing 100% overall response rate in the target Phase 2 population with manageable safety profile. The company also presented preliminary data on eti-cel, a dual CD2...

Allogene Therapeutics won an arbitration against Cellectis regarding CAR-T therapy development rights, securing full control of cemacabtagene ansegedleucel in the U.S., EU, and U.K., while the tribunal rejected Cellectis's financial claims and allegations.

Allogene Therapeutics won a favorable arbitration ruling with Cellectis, reconfirming full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the US, EU, and UK, with a path to acquire full global rights by 2026.

Cellectis reported promising phase 1 clinical trial results for éti-cel, a dual CAR-T cell therapy targeting CD20 and CD22 in relapsed/refractory Non-Hodgkin's Lymphoma, showing an 88% overall response rate and 63% complete response rate. The company plans to explore low-dose IL-2 addition to potentially enhance cell expansion and persistence.